Table 3.
Risk factors associated with the risk of hepatocellular carcinoma development
|
|
Univariate analysis, OR (95% CI)
|
P
value
|
Multivariate analysis, OR (95% CI)
|
P
value
|
| Age (per yr increase) | 1.1 (1.0-1.1) | < 0.001 | 1.1 (1.0-1.1) | < 0.001 |
| Gender (male vs female) | 7.2 (1.7-30.6) | 0.004 | 8.9 (1.1-70.7) | 0.038 |
| Platelet1 (103/mL) | 1.0 (1.0-1.0) | < 0.001 | 1.0 (1.0-1.0) | < 0.001 |
| AFP (ng/mL) | 1.0 (1.0-1.0) | < 0.001 | 1.0 (1.0-1.0) | 0.141 |
| HBeAg status (positive vs negative) | 1.0 (0.4-2.5) | 1.000 | ||
| Diabetes mellitus (yes vs no) | 2.7 (1.1-6.3) | 0.043 | 0.6 (0.2-1.7) | 0.308 |
| NA(s) before ETV/TDF (yes vs no) | 2.0 (0.9-4.5) | 0.143 | ||
| Cirrhosis1 (yes vs no) | 6.3 (2.8-14.2) | < 0.001 | 3.1 (1.1-8.2) | 0.026 |
| Antiviral treatment (ETV vs TDF) | 0.8 (0.3-1.7) | 0.642 | ||
| MVR (no vs yes) | 0.6 (0.2-1.4) | 0.253 | ||
| ALT normalization at month 6 (no vs yes) | 0.4 (0.2-0.9) | 0.043 | 0.2 (0.1-0.7) | 0.009 |
| ALT normalization at month 12 (no vs yes) | 0.4 (0.2-1.0) | 0.101 | ||
| Virological response at month 6 (no vs yes) | 0.8 (0.3-1.9) | 0.622 | ||
| Virological response at month 6 (no vs yes) | 0.7 (0.2-2.2) | 0.530 |
1
Cirrhosis and platelet count were analyzed separately among with other independent variables in logistic regression model as they showed collinearity.
AFP: Alpha-fetoprotein; HBeAg: Hepatitis B e antigen; CI: Confidence interval; ETV: Entecavir; MVR: Maintained virological response; NA(s): Nucleos(t)ide analogue(s); TDF: Tenofovir disoproxil fumarate.